HOPHD
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company's lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, a… Read more
Market Cap & Net Worth: HOPHD (HOPHD)
HOPHD (PINK:HOPHD) has a market capitalization of $11.74K ($11.74K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #44679 globally and #14134 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HOPHD's stock price $1.24 by its total outstanding shares 9468 (9.47K).
HOPHD Market Cap History: 2025 to 2025
HOPHD's market capitalization history from 2025 to 2025. Data shows growth from $11.74K to $11.74K (0.00% CAGR).
HOPHD Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HOPHD's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of HOPHD by Market Capitalization
Companies near HOPHD in the global market cap rankings as of March 18, 2026.
Key companies related to HOPHD by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
HOPHD Historical Marketcap From 2025 to 2025
Between 2025 and today, HOPHD's market cap moved from $11.74K to $ 11.74K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $11.74K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of HOPHD was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.74K USD |
| MoneyControl | $11.74K USD |
| MarketWatch | $11.74K USD |
| marketcap.company | $11.74K USD |
| Reuters | $11.74K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.